A prospective cohort study on the impact of darbepoetin alfa on quality of life in daily practice following anemia treatment guideline revisions

References

• Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004;40:2201-16
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Oechsle K, Hartmann JT. Anaemia in cancer patients: pathophysiology, incidence and treatment. Eur J Clin Investig 2005;35(Suppl 3):26-31
   PubMed Web of Science ®Google Scholar
• Dubray B, Mosseri V, Brunin F, et al. Anemia is associated with lower local–regional control and survival after radiation therapy for head and neck cancer: a prospective study. Radiology 1996;201:553-8
   PubMed Web of Science ®Google Scholar
• Fein DA, Lee WR, Hanlon AL, et al. Pretreatment hemoglobin level influences local control and survival of T1–T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol 1995;13:2077-83
   PubMed Web of Science ®Google Scholar
• Glaser CM, Millesi W, Kornek GV, et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J radiat Oncol Biol Physics 2001;50:705-15
   PubMed Web of Science ®Google Scholar
• Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-74
   PubMed Web of Science ®Google Scholar
• Waters JS, O'Brien ME, Ashley S. Management of anemia in patients receiving chemotherapy. J Clin Oncol 2002;20:601-3
   PubMed Web of Science ®Google Scholar
• Barrett-Lee P, Bokemeyer C, Gascon P, et al. Management of cancer-related anemia in patients with breast or gynecologic cancer: new insights based on results from the European Cancer Anemia Survey. Oncologist 2005;10:743-57
   PubMed Web of Science ®Google Scholar
• Birgegard G, Gascon P, Ludwig H. Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European Cancer Anaemia Survey. Eur J Haematol 2006;77:378-86
   PubMed Web of Science ®Google Scholar
• Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-306
   PubMed Web of Science ®Google Scholar
• Demetri GD. Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy. Br J Canc 2001;84(Suppl 1):31-7
   PubMed Web of Science ®Google Scholar
• Ludwig H, Strasser K. Symptomatology of anemia. Semin Oncol 2001;28(2 Suppl 8):7-14
   PubMed Web of Science ®Google Scholar
• Cella D. The effects of anemia and anemia treatment on the quality of life of people with cancer. Oncology (Williston Park, NY) 2002;16(9 Suppl 10):125-32
   PubMed Web of Science ®Google Scholar
• Steinmetz HT. The role of intravenous iron in the treatment of anemia in cancer patients. Ther Adv Hematol 2012;3:177-91
   PubMedGoogle Scholar
• Steinmetz T, Tschechne B, Harlin O, et al. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol 2013;24:475-82
   PubMed Web of Science ®Google Scholar
• Aapro M, Osterborg A, Gascon P, et al. Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron. Ann Oncol 2012;23:1954-62
   PubMed Web of Science ®Google Scholar
• Steinmetz T, Hellmich M, Neise M, et al. Prediction of the responsiveness to treatment with erythropoiesis-stimulating factors: a prospective clinical study in patients with solid tumors. Oncologist 2007;12:748-55
   PubMed Web of Science ®Google Scholar
• Steinmetz HT, Tsamaloukas A, Schmitz S, et al. A new concept for the differential diagnosis and therapy of anaemia in cancer patients. Support Care Cancer 2010;19:261-9
   PubMed Web of Science ®Google Scholar
• Mortensen FV, Jensen LS, Sorensen HT, et al. Cause-specific mortality associated with leukoreduced, buffy coat-depleted, or no blood transfusion after elective surgery for colorectal cancer: a posttrial 15-year follow-up study. Transfusion 2011;51:259-63
   PubMed Web of Science ®Google Scholar
• Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood 2009;113:3406-17
   PubMed Web of Science ®Google Scholar
• Vamvakas EC, Blajchman MA. Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality. Transfus Med Rev 2010;24:77-124
   PubMed Web of Science ®Google Scholar
• Agarwal AK. Drug safety profile of darbepoetin alfa for anemia of chronic kidney disease. Expert Opin Drug Saf 2009;8:145-53
   PubMed Web of Science ®Google Scholar
• Hedley BD, Allan AL, Xenocostas A. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression. Clin Canc Res 2011;17:6373-80
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43:258-70
   PubMed Web of Science ®Google Scholar
• Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 2008;26:132-49
   PubMed Web of Science ®Google Scholar
• Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood 2008;111:25-41
   PubMed Web of Science ®Google Scholar
• Marchal C, Misset JL, Casadevall N, et al. [Standards & options: recommendations for the use of erythropoiesis-stimulating agents (ESA) in anaemic cancer patients undergoing radiotherapy (2007 update)]. Cancer Radiother 2008;12:126-33
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Kassab-Chahmi D, Casadevall N, et al. [Clinical practice guidelines for the use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, darbepoetin) in anaemic patients with cancer: 2007 update (summary report)]. Bulletin du cancer 2008;95:433-41
   PubMed Web of Science ®Google Scholar
• Aapro MS, Link H. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 2008;13(Suppl 3):33-6
   PubMed Web of Science ®Google Scholar
• Engert A, Josting A, Haverkamp H, et al. Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. J Clin Oncol 2010;28:2239-45
   PubMed Web of Science ®Google Scholar
• Delarue R, Haioun C, Fornecker L, et al. Survival effect of darbepoetin alfa in patients with diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: the LNH03-6B study. J Clin Oncol 2011;29:abstr 9048
   Web of Science ®Google Scholar
• Blohmer JU, Paepke S, Sehouli J, et al. Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. J Clin Oncol 2011;29:3791-7
   PubMed Web of Science ®Google Scholar
• Nitz U, Gluz O, Oberhoff C, et al. Adjuvant chemotherapy with or without darbepoetin alpha in node-positive breast cancer: survival and quality of life analysis from the prospective randomized WSG ARA trial 34th Annual San Antonio Breast Cancer Symposium 2011, 6–10 December 2011, San Antonio, TX, USA, Abstract PD07-06
   Google Scholar
• Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005;23:2606-17
   PubMed Web of Science ®Google Scholar
• Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16:3412-25
   PubMed Web of Science ®Google Scholar
• Steinmetz T, Totzke U, Soling U, et al. Hemoglobin levels that trigger erythropoiesis-stimulating agent treatment decisions for cancer-associated anemia – examination of practice in Germany. Curr Med Res Opin 2008;24:2751-6
   PubMed Web of Science ®Google Scholar
• Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 2010;28:4996-5010
   PubMed Web of Science ®Google Scholar
• Bohlius J, Langensiepen S, Schwarzer G, et al. Erythropoietin for patients with malignant disease. Cochrane Database Syst Rev 2004(3):CD003407
   Google Scholar
• Bohlius J, Wilson J, Seidenfeld J, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2006(3):CD003407
   Google Scholar
• Tonia T, Mettler A, Robert N, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2012;12:CD003407
   PubMed Web of Science ®Google Scholar
• Christodoulou C, Dafni U, Aravantinos G, et al. Effects of epoetin-alpha on quality of life of cancer patients with solid tumors receiving chemotherapy. Anticancer Res 2009;29:693-702
   PubMed Web of Science ®Google Scholar
• Nagel S, Kellner O, Engel-Riedel W, et al. Addition of darbepoetin alfa to dose-dense chemotherapy: results from a randomized phase II trial in small-cell lung cancer patients receiving carboplatin plus etoposide. Clin Lung Canc 2011;12:62-9
   PubMed Web of Science ®Google Scholar
• Carteni G, Giannetta L, Ucci G, et al. Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly. Support Care Cancer 2007;15:1057-66
   PubMed Web of Science ®Google Scholar
• Bell D, Grimes D, Gurney H, et al. Outcomes and predicting response in anaemic chemotherapy patients treated with epoetin alfa. A multicentre, 4-month, open-label study in Australia and New Zealand. Intern Med J 2008;38:751-7
   PubMed Web of Science ®Google Scholar
• Glaspy JA, Charu V, Luo D, et al. Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment arms. Cancer 2009;115:1121-31
   PubMed Web of Science ®Google Scholar
• Rorth M, Madsen KR, Burmolle SH, et al. Effects of darbepoetin alfa with exercise in cancer patients undergoing chemotherapy: an explorative study. Scand J Med Sci Sports 2011;21:369-77
   PubMed Web of Science ®Google Scholar
• Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009;373:1532-42
   PubMed Web of Science ®Google Scholar
• Bohlius J, Schmidlin K, Brillant C, et al. Erythropoietin or darbepoetin for patients with cancer – meta-analysis based on individual patient data. Cochrane Database Syst Rev 2009(3):CD007303
   Google Scholar